1. Web alert

   • David O. Freedman
   • Mark Loeb

   News Pages: 409 - 410

2. Literature alert

   • Edward T. Ryan

   Abstract Pages: 411 - 412

3. US food and drug administration approval of liposomal amphotericin B for the treatment of visceral leishmaniasis: A model for orphan drug development

   • Richard D. Pearson
   • Selma M. B. Jeronimo
   • Susan M. Lareau

   Clinical Trials Review Pages: 415 - 416

4. Vaccination in travelers

   • David R. Hill

   OriginalPaper Pages: 417 - 426

5. Update on hepatobiliary and pulmonary flukes

   • Thomas R. Hawn
   • Elaine C. Jong

   OriginalPaper Pages: 427 - 433

6. Recent developments in the epidemiology, diagnosis, treatment, and prevention of neurocysticercosis

   • A. Clinton White
   • Hector H. Garcia

   OriginalPaper Pages: 434 - 440

7. Amebiasis: Clinical implications of the recognition of Entamoeba dispar

   • Christopher D. Huston
   • William A. Petri

   OriginalPaper Pages: 441 - 447

8. Leishmaniasis at the end of the millennium

   • Richard D. Pearson
   • Susan M. Lareau
   • Selma M. B. Jeronimo

   OriginalPaper Pages: 448 - 452

9. Treatment of community-acquired pneumonia requiring admission to a hospital ward

   • Lionel A. Mandell

   Clinical Trials Review Pages: 455 - 457

10. Ribosomal resistance: Emerging problems and potential solutions

    • George G. Zhanel
    • James A. Karlowsky

    OriginalPaper Pages: 458 - 463

11. Superbugs: How they evolve and minimize the cost of resistance

    • Donald E. Low
    • James D. Kellner
    • Gerard D. Wright

    OriginalPaper Pages: 464 - 469

12. New fluoroquinolones: Real and potential roles

    • Peter Ball

    OriginalPaper Pages: 470 - 479

13. Quinupristin-dalfopristin

    • Peter Linden

    OriginalPaper Pages: 480 - 487

14. "Essentiality" testing: Looking for new antimicrobial targets

    • David Knowles
    • Gary Patou

    OriginalPaper Pages: 488 - 494

15. Viral load monitoring in HIV Infection

    • Mark Holodniy

    OriginalPaper Pages: 497 - 503